Up to 43 biosimilars for conditions that include diabetes, immunology, bone health and ophthalmology are expected to enter the market by 2029 and drug distributor Cardinal Health reports that biosimilar are on track to reduce U.S. drug spending by $133 billion by 2025. However, insurers and doctors have been slow to adopt biosimilars, and it remains to be seen whether, or to what extent, that will change. Cardinal Health predicts federal and state governments will institute policies that promote biosimilars,...